Latest Patents News

Page 12 of 104
Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.
Ada Torres
Ada Torres
28 Aug 2026
Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.
Ada Torres
Ada Torres
28 Aug 2026
Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.
Maxwell Dee
Maxwell Dee
28 Aug 2026
Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.
Ada Torres
Ada Torres
27 Aug 2026
Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.
Ada Torres
Ada Torres
27 Aug 2026
Ainsworth Game Technology’s first half 2026 results reveal a sharp revenue drop driven by North American and Latin American market pressures, offset partially by Asia Pacific growth and a key patent licensing deal.
Victor Sage
Victor Sage
26 Aug 2026
Advanced Braking Technology Ltd (ASX: ABV) posted a 22.7% revenue increase to $23.48 million and a 16.6% rise in net profit after tax to $2.075 million for FY26, driven by international expansion and advances in autonomous braking technology.
Victor Sage
Victor Sage
26 Aug 2026
NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.
Ada Torres
Ada Torres
25 Aug 2026
Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.
Ada Torres
Ada Torres
25 Aug 2026
Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.
Ada Torres
Ada Torres
25 Aug 2026
Zeotech Limited’s zeoteCH4® technology slashed methane emissions by an average 92% in a six-month landfill trial at North Burnett Regional Council, confirming its promise as a practical methane mitigation solution under real-world conditions.
Victor Sage
Victor Sage
25 Aug 2026
Metal Powder Works secures its biggest-ever purchase order for pure copper powder from Embassy Powdered Metals, marking its debut in the copper infiltration segment and accelerating capacity expansion plans.
Maxwell Dee
Maxwell Dee
24 Aug 2026

Browse the archive

Full archive